Evidence map›Paper›PMID 39136125›Full record

ArticleACS infectious diseases2024

Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects.

Franziska Marwitz, Gabriela Hädrich, Natalja Redinger, Karen F W Besecke, Feng Li, Nadine Aboutara, Simone Thomsen, Michaela Cohrs, Paul Robert Neumann, Henrike Lucas and 7 more

Abstract read
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Franziska MarwitzBioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Parkallee 1-40, Borstel 23845, Germany.
Gabriela HädrichDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2 ,Vienna 1090, Austria.
Natalja RedingerCellular Microbiology, Research Center Borstel, Leibniz Lung Center, Parkallee 1-40 ,Borstel 23845, Germany.
Karen F W BeseckeRodos Biotarget GmbH, Feodor-Lynen-Straße 31, Hannover 30625, Germany.
Feng LiDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2 ,Vienna 1090, Austria.
Nadine AboutaraBioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Parkallee 1-40, Borstel 23845, Germany.
Simone ThomsenBioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Parkallee 1-40, Borstel 23845, Germany.
Michaela CohrsInstitute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Str. 3, Halle/Saale 06120, Germany.ORCID 0000-0003-1195-534X
Paul Robert NeumannInstitute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Str. 3, Halle/Saale 06120, Germany.
Henrike LucasInstitute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Str. 3, Halle/Saale 06120, Germany.
Julia KollanInstitute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Str. 3, Halle/Saale 06120, Germany.
Constantin HozsaRodos Biotarget GmbH, Feodor-Lynen-Straße 31, Hannover 30625, Germany.
Robert K GieselerRodos Biotarget GmbH, Feodor-Lynen-Straße 31, Hannover 30625, Germany.
Dominik SchwudkeBioanalytical Chemistry, Research Center Borstel, Leibniz Lung Center, Parkallee 1-40, Borstel 23845, Germany.ORCID 0000-0002-1379-9451
Marcus FurchRodos Biotarget GmbH, Feodor-Lynen-Straße 31, Hannover 30625, Germany.
Ulrich SchaibleGerman Center for Infection Research, Thematic Translational Unit Tuberculosis, Borstel 23845, Germany.
Lea Ann DaileyDepartment of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2 ,Vienna 1090, Austria.ORCID 0000-0002-4908-7122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposomal formulations of antibiotics for inhalation offer the potential for the delivery of high drug doses, controlled drug release kinetics in the lung, and an excellent safety profile. In this study, we evaluated the

Indexed as

Administration, IntranasalAntitubercular AgentsDiarylquinolinesLiposomesMice, Inbred BALB CMycobacterium tuberculosisAnimalsDisease Models, AnimalFemaleFucoseLungMiceMice, Inbred C3HTuberculosisAntitubercular AgentsbedaquilineDiarylquinolinesFucoseLiposomesbedaquilineinhalationliposomespharmacokineticstuberculosis

Identifiers

PMID39136125
PMCPMC11406518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.